Arsenic trioxide in the treatment of acute promyelocytic leukemia

Wiesław Wiktor Jędrzejczak

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2001
vol. 5

Send email

Copy url:

abstract:

Arsenic trioxide in the treatment of acute promyelocytic leukemia

Wiesław Wiktor Jędrzejczak

Współcz Onkol (2001) vol. 5, 4 (145-146)

Online publish date: 2003/07/16

View full text Get citation

Arsenic trioxide solely or in combination may induce complete remission in virtually all cases of acute promyelocytic leukemia, that currently remains its only clinical indication. Contrary to some expectations when administered intravenously it has only mild adverse effects. Arsenic trioxide acts through induction of apoptosis and differentiation and influences also cells with high expression of multidrug resistance genes. Its precise place in the treatment of acute promyolocytic leukemia is still under investigation. Similarly, a search for other neoplasms sensitive to its action continues.

keywords:

Arsenic trioxide in the treatment of acute promyelocytic leukemia

Wiesław Wiktor Jędrzejczak

arsenic trioxide, acyte myeloblastic leukemia, apoptosis, ATRA